Aurinia Pharmaceuticals Inc. (AUPH) Receives Buy Rating from Canaccord Genuity
Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH)‘s stock had its “buy” rating restated by investment analysts at Canaccord Genuity in a report released on Saturday. They currently have a $10.00 target price on the stock. Canaccord Genuity’s target price indicates a potential upside of 112.77% from the stock’s current price.
Several other brokerages have also recently weighed in on AUPH. HC Wainwright initiated coverage on Aurinia Pharmaceuticals in a report on Thursday, June 30th. They issued a “buy” rating and a $7.00 price objective for the company. FBR & Co reissued an “outperform” rating and set a $9.00 price target on shares of Aurinia Pharmaceuticals in a report on Monday, August 15th. Finally, Leerink Swann reissued an “outperform” rating and set a $7.00 price target on shares of Aurinia Pharmaceuticals in a report on Wednesday, July 6th. One investment analyst has rated the stock with a hold rating and four have assigned a buy rating to the stock. The company currently has an average rating of “Buy” and a consensus target price of $7.75.
Aurinia Pharmaceuticals (NASDAQ:AUPH) opened at 4.70 on Friday. The company has a 50-day moving average price of $2.45 and a 200 day moving average price of $2.78. Aurinia Pharmaceuticals has a 12-month low of $1.42 and a 12-month high of $5.69. The company’s market cap is $165.84 million.
An institutional investor recently raised its position in Aurinia Pharmaceuticals stock. Lombard Odier Asset Management USA Corp boosted its position in Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) by 2.8% during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 102,294 shares of the company’s stock after buying an additional 2,813 shares during the period. Lombard Odier Asset Management USA Corp owned about 0.29% of Aurinia Pharmaceuticals worth $283,000 at the end of the most recent quarter. Hedge funds and other institutional investors own 20.04% of the company’s stock.
Aurinia Pharmaceuticals Company Profile
Aurinia Pharmaceuticals Inc is a Canada-based clinical-stage biopharmaceutical company operating in the field of nephrology and autoimmunity. The Company’s primary business is the development of a therapeutic drug to treat autoimmune diseases, in particular lupus nephritis (LN). It is focused on the development of its lead compound voclosporin, a therapeutic immunomodulating drug candidate, which is a second-generation calcineurin inhibitors (CNI) to treat patients afflicted with LN.
Receive News & Stock Ratings for Aurinia Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aurinia Pharmaceuticals Inc. and related stocks with our FREE daily email newsletter.